Compare · AVTX vs NVO
AVTX vs NVO
Side-by-side comparison of Avalo Therapeutics Inc. (AVTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $168.79B, about 265.8x AVTX ($635.0M).
- AVTX has been more active in the news (5 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for AVTX).
- Company
- Avalo Therapeutics Inc.
- Novo Nordisk A/S
- Price
- $11.27-6.20%
- $38.82-1.05%
- Market cap
- $635.0M
- $168.79B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 5
- 4
- Recent ratings
- 20
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVTX
- SEC Form 4 filed by Director Lind Kevin Robert
- SEC Form 4 filed by Director Jain Rita
- SEC Form 4 filed by Director Philip Ron M
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Avalo Therapeutics to Present at the European Academy of Dermatology and Venereology (EADV) 2026 Congress
- Chief Financial Officer Sullivan Christopher Ryan exercised 12,394 shares at a strike of $9.88 and sold $202,437 worth of shares (12,394 units at $16.33) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Sullivan Christopher Ryan exercised 10,185 shares at a strike of $8.04 and sold $179,457 worth of shares (10,185 units at $17.62) as part of a pre-agreed trading plan (SEC Form 4)
- Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Avalo Therapeutics to Participate in Upcoming Investor Conferences
- Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank